Trials / Completed
CompletedNCT00822211
Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 404 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of vildagliptin 50 mg bid compared to placebo as an add-on therapy to metformin in Chinese patients with T2DM inadequately controlled by metformin alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin 50 mg bid | |
| DRUG | Vildagliptin 50 mg qd | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2009-01-14
- Last updated
- 2016-11-18
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00822211. Inclusion in this directory is not an endorsement.